GLP 1 Obesity Drug Pipeline 2026: Timeline

How Should Researchers Read This Timeline?

The most useful way to read the 2026 obesity pipeline is to separate four event types: approvals already won, pending FDA decisions, Phase 3 readouts that feed future filings, and post-approval launch checkpoints. That framing keeps this page focused on timing instead of duplicating the direct approval answers handled by the drug-specific status pages.

In practice, that means Foundayo now belongs in the post-approval bucket, CagriSema stays in the pending-decision bucket, and retatrutide remains in the readout-to-filing bucket until Lilly submits; Lilly says it will file for US approval no later than Q1 2027. Programs like survodutide, VK2735, and zenagamtide matter because they can change the next filing wave even without an immediate FDA action.

If you need the definitive regulatory answer for one drug, use the linked status page. If you need the master collection of approval pages, start with the Approval Trackers hub. If you need the sequence of what lands next, what reads out next, and what could move the pipeline next, this calendar is the better page.

Which 2026 Windows Matter Most?

The highest-signal regulatory window left in 2026 is CagriSema. After Novo Nordisk’s December 2025 filing, the key question is no longer whether the data set exists, but whether the FDA converts that package into the first approved amylin-plus-GLP-1 obesity product in late 2026.

The densest readout window belongs to retatrutide. Every positive TRIUMPH update increases confidence in Lilly’s future filing package, but each readout is still a catalyst rather than a final approval event. That is why this page tracks milestone sequencing while the retatrutide status page handles the yes-or-no question.

The third important window is the oral segment. Foundayo has already changed the answer on oral obesity drugs, so the remaining question is whether launch uptake, payer access, and later-wave programs like oral VK2735 can reshape the category by year-end.

Why Do Oral and Label-Expansion Dates Matter?

The oral timeline no longer starts with a hypothetical approval question. It now starts with two approved products: the Wegovy pill and Foundayo. That shifts the relevant 2026 events toward launch execution, access checkpoints, and the next datasets that could support broader label or geographic expansion.

That is also why oral VK2735 matters even before approval. Its job in the 2026 calendar is not to answer a status question; it is to show whether a later-wave oral dual agonist can build a competitive filing path against two already-approved oral GLP-1 products.

The same logic applies to comorbidity programs. Sleep apnea, MASH, osteoarthritis, HFpEF, and diabetes readouts are not side stories. They help determine how broad future labels can become, which is why they belong in the calendar even when they do not create an immediate obesity approval event.

What CagriSema Catalysts Are Expected in 2026?

CagriSema (cagrilintide + semaglutide) is the closest obesity drug to an FDA decision in 2026. Novo Nordisk filed the NDA in December 2025 and the FDA has accepted the submission, with review tracking through 2026. On September 21, 2026, Novo Nordisk restated that it expects a US decision in Q4 2026; no FDA decision had been announced as of October 14, 2026. For the dedicated answer-style page, see CagriSema FDA approval status; for every pending submission, the obesity drug approval tracker for 2026.

The filing is supported by the REDEFINE clinical program. The pivotal REDEFINE 1 trial showed 22.7% mean weight loss at 68 weeks if all participants adhered (20.4% versus 3.0% on placebo in the primary analysis published in the New England Journal of Medicine), significantly exceeding the semaglutide-alone arm. CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide), delivered from a single dual-chamber pen. Amylin-based combinations such as CagriSema are also being watched for possible reductions in gastrointestinal side effects relative to standalone GLP-1 drugs, although in REDEFINE 1 gastrointestinal adverse events affected 79.6% of participants on CagriSema versus 73.8% on semaglutide alone and 39.9% on placebo. A REDEFINE 1 body-composition sub-analysis presented at the European Congress on Obesity (ECO 2026, Istanbul, May 12–15) showed that in patients reaching ≥30% weight loss, fat-mass share fell from 46.3% to 33.2% — supporting a fat-preferential loss profile even though substantial weight loss can also include some reduction in muscle mass.

At its September 21, 2026 Capital Markets Day, Novo Nordisk said it expects a full U.S. launch at the start of 2027 if CagriSema is approved, with REDEFINE 11 and CagriSema HD readouts planned in H1 2027 and H1 2028. Pediatric data are years away: a Phase 3 trial in children and adolescents aged 8–18 (NCT07253285) has an estimated primary completion in March 2030, and REIMAGINE YOUNG (NCT07282613, ages 10–18 with type 2 diabetes) in September 2029. REDEFINE 6 (NCT05996848) is a completed trial in 300 Chinese adults, not an adolescent study. The REDEFINE 3 cardiovascular outcomes trial runs beyond 2026 (primary completion estimated September 2027).

What Retatrutide Data Is Coming in 2026?

Retatrutide is Eli Lilly’s triple agonist (GLP-1, GIP, and glucagon receptor agonist), with multi-agonist therapies being developed to approach bariatric-surgery-level efficacy, and the most potent weight-loss drug in Phase 3 development. The TRIUMPH-4 trial reported topline results on December 11, 2025 showing 28.7% mean body weight reduction at 68 weeks — the highest figure ever reported in a Phase 3 obesity trial. Triple-receptor agonists pair appetite suppression with higher energy expenditure through glucagon activity, an energy-expenditure effect shown for retatrutide in diet-induced obese mice (Coskun et al., Cell Metabolism, 2022). For a mechanistic deep dive, see our explainer on the triple agonist GIP, GLP-1, and glucagon pathway.

Multiple retatrutide readouts have already landed in 2026. TRANSCEND-T2D-1 (Phase 3 in type 2 diabetes) reported HbA1c reduction of 1.7–2.0% across the 4, 9, and 12 mg doses and weight loss of 11.5–16.8% (roughly 25–37 lbs) over 40 weeks versus a 2.5% placebo weight change. Full results were presented at the American Diabetes Association Scientific Sessions on June 5–8, 2026 and simultaneously published in The Lancet. Discontinuation ran 2.2–5.1% across doses, with nausea (16.4–26.5%), diarrhea (18.7–26.3%), and vomiting (15.0–17.6%) as the dominant adverse events.

TRIUMPH-1, the 80-week obesity weight-management pivotal trial that supports the filing package, reported topline results on May 21, 2026. All three doses (4, 9, 12 mg) met the primary and key secondary endpoints, with mean weight loss of 19.0%, 25.9%, and 28.3% at 80 weeks by the efficacy estimand (up to 25% by the treatment-regimen estimand; n=2,339); a blinded BMI ≥35 extension reached 30.3% at 104 weeks. On the April 30 Q1 2026 earnings call, Lilly had guided this readout for “later this quarter.” Detailed results were presented at the ADA Scientific Sessions in June 2026, and the trial was published in the New England Journal of Medicine on September 29, 2026 (doi:10.1056/NEJMoa2604169).

Lilly’s June 6 full-data release also reported TRIUMPH-1 basket outcomes beyond body weight: WOMAC knee-osteoarthritis pain fell by up to 4.3 points (73.1%), and the apnea-hypopnea index in the moderate-to-severe OSA basket fell by up to 36.1 events per hour (60.6%). The broader strategy for retatrutide and similar agents is increasingly aimed at organ-protection benefits in obesity-related disease, not weight alone. These are trial findings for an investigational compound, not approved-indication claims.

TRIUMPH-2 and TRIUMPH-3 reported positive toplines on July 23, 2026. TRIUMPH-2 (obesity with type 2 diabetes, 80 weeks) reported 12.7%, 19.1% and 20.8% weight loss at 4, 9 and 12 mg versus 4.0% on placebo (efficacy estimand), with A1C down by up to 1.6 points. TRIUMPH-3 (severe obesity with established cardiovascular disease, NCT05882045, 80 weeks) reported 21.6% and 22.6% at 9 and 12 mg versus 3.2%; its MACE-5 hazard ratio was 0.82 (95% CI 0.55–1.22), but the trial was a weight trial and was not powered for cardiovascular outcomes, which are being tested in TRIUMPH-Outcomes. Emerging obesity therapies are also being evaluated for effects on markers such as blood pressure and systemic inflammation.

Remaining retatrutide Phase 3 readouts include TRIUMPH-5 (head-to-head versus tirzepatide in obesity, NCT06662383; ClinicalTrials.gov primary completion estimated November 2026), TRIUMPH-6 (weight maintenance, estimated 2028), TRIUMPH-7 (obesity with chronic low back pain, estimated 2027), TRIUMPH-8 and -9, the TRIUMPH-Outcomes cardiovascular and kidney trial (NCT06383390, estimated 2029) and the SYNERGY-Outcomes MASLD liver-outcomes trial (NCT07165028, estimated 2030). Long-term weight maintenance remains a major research priority, which is why studies such as TRIUMPH-6 matter. In type 2 diabetes, TRANSCEND-T2D-2 (versus semaglutide) reached primary completion on August 27, 2026, and TRANSCEND-T2D-3 is estimated for October 2026. Obstructive sleep apnea and knee osteoarthritis data came from the TRIUMPH-1 basket cohorts and from TRIUMPH-4, not from separate trials. On the Q1 call, Lilly also began framing retatrutide commercially as both a “deeper weight loss” agent and a potential add-on to existing incretins for incremental loss, while some developers are also pursuing extended-duration dosing to reduce injection frequency.

Lilly now cites five positive Phase 3 studies and says it will file for US approval no later than Q1 2027, covering obesity, obstructive sleep apnea and knee osteoarthritis pain. Retatrutide is not approved anywhere; an FDA decision would follow review of that submission. For trial-by-trial detail, see the TRIUMPH trial tracker. See our retatrutide vs tirzepatide vs CagriSema comparison for how these three leading candidates stack up.

What Is Next for Foundayo (Orforglipron) Oral GLP-1 in 2026?

Orforglipron is no longer a future-approval story in obesity. Lilly’s oral non-peptide GLP-1 was FDA approved as Foundayo on April 1, 2026, making it the first oral GLP-1 for obesity that can be taken at any time of day without food or water restrictions. The 2026 calendar for Foundayo is now about launch execution, the type 2 diabetes label, and ex-U.S. expansion.

In mid-April, Lilly reported topline results from ACHIEVE-4, the seventh and final Phase 3 in the global type 2 diabetes registration package. ACHIEVE-4 met non-inferiority on MACE-4 versus insulin glargine and reported a numerically favorable cardiovascular profile in preplanned unadjusted analyses, with no hepatic safety signal. Lilly reported the U.S. type 2 diabetes submission in its Q2 2026 results on August 5, 2026 (Foundayo is already FDA-approved for weight management; the type 2 diabetes indication is a separate submission). Detailed ACHIEVE-4 results on September 30, 2026 showed a MACE-4 hazard ratio of 0.84 (95% CI 0.59–1.20) versus insulin glargine.

Outside the U.S., the UAE’s Emirates Drug Establishment approved Foundayo on April 3, 2026 (the second country to register it), Saudi Arabia’s SFDA registered it on August 2, 2026, and the UK MHRA authorised Foundayo on August 10, 2026 for weight management and type 2 diabetes, the first authorisation in Europe. Reviews are also ongoing in other countries.

Early U.S. launch metrics, disclosed on the April 30 Q1 earnings call: pharmacy availability began April 9; more than 20,000 patients were on therapy by end of April; more than 8,000 prescribers had written a Foundayo prescription, roughly one-third new to oral GLP-1s; about 80% of scripts were classified as new to the GLP-1 class. The first full launch week ran roughly 5,612 prescriptions by week 3 — modest next to the Wegovy pill, which posted more than 18,000 prescriptions in its first week post-January 5 launch. Uptake has since grown: weekly U.S. Foundayo prescriptions reached 64,268 in the week reported on October 2, 2026 (IQVIA data cited by Citi, via Fierce Pharma).

Foundayo’s competitive case still rests on convenience: it is a once-daily pill with no food or water dosing restrictions, unlike the Wegovy pill, which requires fasting conditions. That means the 2026 calendar is really a launch-comparison timeline between two approved oral GLP-1 products plus the next investigational oral entrants. Newer cash-pay offers have also pushed some monthly obesity-drug pricing into roughly the $149-$299 range (U.S. self-pay offers for the Wegovy pill and Foundayo, according to Novo Nordisk and Lilly, checked October 14, 2026). Even with lower prices, demand has continued to grow, which is why these early launch metrics still matter in the broader obesity treatment market.

For the direct regulatory answer, use the orforglipron status page. For the post-approval label, pricing, and market-impact view, use the Foundayo deep dive. For a broader oral segment comparison, see our oral obesity drugs 2026 guide.

Where Does Survodutide Stand in 2026?

Survodutide (Boehringer Ingelheim / Zealand Pharma) is a dual GLP-1/glucagon receptor agonist in the Phase 3 SYNCHRONIZE program. The program includes SYNCHRONIZE-1 (obesity without type 2 diabetes), SYNCHRONIZE-2 (obesity with type 2 diabetes), SYNCHRONIZE-MASLD, SYNCHRONIZE-CVOT (cardiovascular safety; completed June 2026), trials in Japan and China, and the newer SYNCHRONIZE-T2D, -HERA and -START studies. MASH runs separately in LIVERAGE (primary completion estimated December 2031) and LIVERAGE-Cirrhosis (estimated June 2029), both still recruiting.

On April 28, 2026, Boehringer reported SYNCHRONIZE-1 Phase 3 topline: weight loss of up to 16.6% at 76 weeks versus 3.2% on placebo in adults with obesity or overweight without type 2 diabetes, using the efficacy estimand. The New England Journal of Medicine paper (June 7, 2026) gave the primary treatment-regimen results by dose: −12.2% with 3.6 mg and −13.0% with 6.0 mg versus −5.4% on placebo. The June ADA analysis reported visceral-fat reduction up to 34.0%, liver-fat reduction up to 63.1%, and lean mass accounting for no more than 10.8% of total tissue-mass change. Treatment goals are increasingly framed around preserving muscle mass and improving overall health, not just maximizing weight loss. That kind of body-composition readout, alongside changes in liver fat content, supports a broader efficacy profile. Rapid weight loss can also increase gallstone risk. GI adverse-event discontinuation was 19.0% versus 2.9% on placebo. Mazdutide, another GLP-1/glucagon dual agonist, had already reported Phase 3 results in China (GLORY-1, New England Journal of Medicine, 2025).

The 16.6% figure sits clearly below the Phase 2 best-dose 19% benchmark and below the CagriSema (22.7%) and retatrutide TRIUMPH-4 (28.7%) Phase 3 reference points. That framing carried into SYNCHRONIZE-2 (obesity or overweight with type 2 diabetes), which reported up to 13.1% weight loss at 76 weeks versus 3.1% on placebo (efficacy estimand) at EASD on October 1, 2026, published the same day in the New England Journal of Medicine, a significant reduction versus placebo. SYNCHRONIZE-CVOT results are next: Boehringer says it will present them later in 2026. LIVERAGE and LIVERAGE-Cirrhosis continue to recruit. No survodutide regulatory filing has been announced.

Survodutide’s dual-agonist mechanism (GLP-1 + glucagon) differs from retatrutide’s triple-agonist approach and from CagriSema’s GLP-1/amylin combination, making it a structurally distinct competitive entry. Phase 2 data also showed liver-fat reduction, positioning it as a potential MASH therapy candidate alongside the obesity indication, while glucagon-based therapies are also being tracked for broader metabolic effects, including blood pressure and systemic inflammatory changes. For help evaluating these candidates, see our analysis of the best obesity drug in 2026.

Mazdutide (IBI362): The Dual GLP-1/Glucagon Receptor Agonist and GLP-1 Receptor Agonists

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics under license from Eli Lilly. It is not a triple agonist — unlike retatrutide, mazdutide omits GIP receptor engagement entirely, activating only two receptor targets (GLP-1R and GCGR). The compound received its first regulatory approval in China in 2025 for type 2 diabetes and weight management at the 4 mg and 6 mg doses. The 9 mg adult-obesity dose hit primary and all key secondary endpoints in GLORY-2 (Nov 2025) in the Chinese population, at up to 20.1% mean weight loss, Innovent says the 9 mg application for adult weight management was submitted in November 2025 and accepted by China’s NMPA, and GLORY-2 was published in JAMA on June 8, 2026; no 9 mg approval had been announced as of October 12, 2026.

On May 12, 2026, Innovent announced a broad mazdutide clinical trials slate at ADA 2026 (June 5–8, New Orleans): full GLORY-2 adult obesity data, DREAMS-3 (Phase 3b head-to-head versus semaglutide in Chinese T2D + obesity), and a Phase 1b adolescent obesity PK/safety study. A MASH preclinical poster is also on the program.

Mazdutide’s scientific importance extends beyond its clinical results. Because it isolates GLP-1 + glucagon receptor activation without GIP, unlike triple agonists such as retatrutide that also engage glucose dependent insulinotropic polypeptide, comparing mazdutide outcomes to retatrutide’s GLP-1 + GIP + glucagon results allows researchers to infer the approximate contribution of GIP receptor agonism to metabolic outcomes. This makes mazdutide a critical reference compound for understanding why triple agonists achieve higher weight loss than dual agonists. The Chinese regulatory pathway is distinct from the U.S./EU process, so an NMPA approval would not directly translate into FDA action.

What Other Obesity Treatment Drugs Have 2026 Milestones?

Wegovy pill (oral semaglutide 25 mg). FDA approved in late 2025, the Wegovy pill is the first oral GLP-1 drug indicated to treat obesity, building on the Rybelsus oral semaglutide platform originally approved for diabetes. OASIS 4 showed 16.6% weight loss at 64 weeks if all participants adhered (13.6% versus 2.2% on placebo in the primary treatment-policy analysis). Q1 2026 sales reached approximately DKK 2.26 billion (~US$354M), roughly double consensus estimates, with more than 2 million prescriptions written cumulatively since the January 5 launch and more than 18,000 scripts in the first launch week. Novo Nordisk raised its 2026 sales guidance on the strength of the Wegovy pill ramp. The European Commission approved the Wegovy pill on July 15, 2026, alongside a single-dose 7.2 mg Wegovy pen; in the U.S., the FDA approved Wegovy HD (semaglutide 7.2 mg injection) on March 19, 2026. For severe obesity, bariatric surgery remains an important option alongside drug therapy.

Zenagamtide (formerly amycretin), Novo Nordisk. This unimolecular GLP-1/amylin agonist has obesity Phase 3 programs under way in both formulations: the subcutaneous AMAZE trials began with AMAZE 1 on February 24, 2026, and the oral AMAZE 9 trial started on August 31, 2026. At ADA 2026, Phase 2 T2D data showed HbA1c reductions up to 1.71 percentage points and weight loss up to 14.6% at 36 weeks. Its type 2 diabetes Phase 3 trial AMBITION 7 (NCT07797335) started in August 2026.

VK2735 (Viking Therapeutics). The subcutaneous formulation’s two pivotal Phase 3 obesity trials are now both fully enrolled: VANQUISH-2 completed enrollment on March 26, 2026 and VANQUISH-1 was reported fully enrolled in Viking’s Q1 2026 results on April 29, 2026. Both Phase 3 readouts are expected in 2027. The oral formulation’s full 13-week Phase 2 VENTURE-2 dataset was presented at the European Congress on Obesity on May 12, 2026: up to 12.2% mean weight loss at 120 mg over 13 weeks, no plateau through Week 13, and roughly 80% of participants reaching at least 10% weight loss at the top dose.

Viking’s oral Phase 3 trials SUNRISE-1 (NCT07868835) and SUNRISE-2 in type 2 diabetes (NCT07868939) were first posted on ClinicalTrials.gov on October 9, 2026 (submitted October 5); as of October 12, 2026 neither was recruiting yet, with starts estimated for October 15 and 16. In the subcutaneous maintenance study (Part 1 topline, September 22, 2026), 21 weeks of weekly dosing gave about 16–19% weight loss versus about 0% on placebo, and participants moved to monthly or every-other-week injections kept up to 90% or 97% of that loss versus 61% on placebo (exploratory endpoints). Part 2, which adds oral maintenance arms in about 195 adults, started on October 6, 2026, with results expected in 2027.

Petrelintide (Roche / Zealand Pharma). This amylin analog reported 10.7% weight loss at 42 weeks in the Phase 2 ZUPREME-1 trial. On April 29, 2026, Zealand and Roche jointly announced that petrelintide would advance to Phase 3, and on September 22, 2026 Zealand announced the start of the registrational ZUPREME program (ZUPREME-3, -4 and -5, about 7,000 participants). On October 7, 2026, ZUPREME-2 reported up to 9.2% weight loss versus 2.0% on placebo at week 28 in people with type 2 diabetes.

Mazdutide (Innovent / Eli Lilly China). A dual GLP-1/glucagon agonist in the GLORY Phase 3 program in China; GLORY-2 met endpoints in November 2025 at the 9 mg adult-obesity dose. At ADA 2026, DREAMS-3 reported 10.3% versus 6.0% mean weight loss and 2.03 versus 1.84 percentage-point HbA1c reductions for mazdutide 6 mg versus semaglutide 1 mg at week 32; 48.0% versus 21.0% reached HbA1c below 7% plus at least 10% weight loss. The 9 mg adult-obesity application has been under NMPA review since November 2025.

Monlunabant (Novo Nordisk). Monlunabant was an emerging program among cannabinoid receptor blockers, acting as a peripherally restricted CB1 inverse agonist; reported neuropsychiatric issues have generally been mild to moderate, but Novo Nordisk terminated its development for portfolio considerations (first-half 2026 financial report, August 4, 2026).